Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Active, not recruiting Phase 2 Interventional

Testing Atezolizumab Alone or Atezolizumab Plus Bevacizumab in People With Advanced Alveolar Soft Part Sarcoma

ClinicalTrials.gov ID: NCT03141684

Public ClinicalTrials.gov record NCT03141684. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 5:13 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 2 Study of Anti-PD-L1 Antibody (Atezolizumab) in Alveolar Soft Part Sarcoma

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This phase II trial studies how well atezolizumab or atezolizumab plus bevacizumab works in treating patients with alveolar soft part sarcoma that has not been treated, has spread from where it started to other places in the body (advanced) and cannot be removed by surgery (unresectable). Atezolizumab works by unblocking the immune system, allowing the immune system cells to recognize and then attack tumor cells. Bevacizumab works by controlling the growth of new blood vessels. Giving atezolizumab alone or atezolizumab with bevacizumab may shrink the cancer.

Study identification

NCT ID
NCT03141684
Recruitment status
Active, not recruiting
Study type
Interventional
Phase
Phase 2
Enrollment
63 participants

Conditions and interventions

Eligibility (public fields only)

Age range
2 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Apr 25, 2017 (Actual)
Primary completion
Oct 31, 2027 (Estimated)
Completion
Oct 31, 2027 (Estimated)
Last update posted
Oct 14, 2026

2017 – 2027

United States locations

U.S. sites
42
U.S. states
15
U.S. cities
31
Facility City State ZIP Site status
Keck Medicine of USC Buena Park Buena Park California 90621 —
Keck Medicine of USC Koreatown Los Angeles California 90020 —
Los Angeles General Medical Center Los Angeles California 90033 —
USC / Norris Comprehensive Cancer Center Los Angeles California 90033 —
USC Norris Oncology/Hematology-Newport Beach Newport Beach California 92663 —
Keck Medical Center of USC Pasadena Pasadena California 91105 —
University of California Davis Comprehensive Cancer Center Sacramento California 95817 —
Smilow Cancer Hospital-Derby Care Center Derby Connecticut 06418 —
Smilow Cancer Hospital Care Center-Fairfield Fairfield Connecticut 06824 —
Smilow Cancer Hospital Care Center - Guilford Guilford Connecticut 06437 —
Smilow Cancer Hospital Care Center at Saint Francis Hartford Connecticut 06105 —
Smilow Cancer Center/Yale-New Haven Hospital New Haven Connecticut 06510 —
Yale University New Haven Connecticut 06520 —
Yale-New Haven Hospital North Haven Medical Center North Haven Connecticut 06473 —
Smilow Cancer Hospital-Orange Care Center Orange Connecticut 06477 —
Smilow Cancer Hospital-Torrington Care Center Torrington Connecticut 06790 —
Smilow Cancer Hospital Care Center-Trumbull Trumbull Connecticut 06611 —
Smilow Cancer Hospital-Waterbury Care Center Waterbury Connecticut 06708 —
Smilow Cancer Hospital Care Center - Waterford Waterford Connecticut 06385 —
Emory University Hospital Midtown Atlanta Georgia 30308 —
University of Iowa/Holden Comprehensive Cancer Center Iowa City Iowa 52242 —
Johns Hopkins University/Sidney Kimmel Cancer Center Baltimore Maryland 21287 —
National Cancer Institute Developmental Therapeutics Clinic Bethesda Maryland 20892 —
National Institutes of Health Clinical Center Bethesda Maryland 20892 —
NCI - Center for Cancer Research Bethesda Maryland 20892 —
Massachusetts General Hospital Cancer Center Boston Massachusetts 02114 —
Brigham and Women's Hospital Boston Massachusetts 02115 —
Beth Israel Deaconess Medical Center Boston Massachusetts 02215 —
Dana-Farber Cancer Institute Boston Massachusetts 02215 —
Mayo Clinic in Rochester Rochester Minnesota 55905 —
Siteman Cancer Center at West County Hospital Creve Coeur Missouri 63141 —
Washington University School of Medicine St Louis Missouri 63110 —
Siteman Cancer Center-South County St Louis Missouri 63129 —
Children's Hospital and Medical Center of Omaha Omaha Nebraska 68114 —
University of Nebraska Medical Center Omaha Nebraska 68198 —
NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center New York New York 10032 —
Duke University Medical Center Durham North Carolina 27710 —
Ohio State University Comprehensive Cancer Center Columbus Ohio 43210 —
UPMC Hillman Cancer Center Pittsburgh Pennsylvania 15232 —
Vanderbilt Breast Center at One Hundred Oaks Nashville Tennessee 37204 —
Vanderbilt University/Ingram Cancer Center Nashville Tennessee 37232 —
UT MD Anderson Cancer Center Houston Texas 77030 —

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT03141684, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Oct 14, 2026 · Synced Oct 21, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT03141684 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →